The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.
April 24th 2024
Jharna M. Patel, MD, discusses the utility of ChatGPT in genetic counseling for patients with gynecologic cancers.
The Latest on Acute Lymphocytic Leukemia
View More
A Focus on Acute Myeloid Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Emerging Data on Anti-HER2 ADCs in Patients With Cervical Cancer
January 10th 2024Bradley Monk, MD, shares the promising potential of anti-HER2 therapy in cervical cancer and discusses encouraging results from recent trials, emphasizing the importance of testing for HER2 and considering anti-HER2 antibody drug conjugates as a treatment option.
2023 Yields Several Promising Trial Updates in dMMR/pMMR Endometrial Cancer
Eirwen M. Miller, MD, highlights data that have impacted the treatment armamentarium for patients with endometrial cancer and mismatch repair–deficient or mismatch repair–proficient disease throughout the course of 2023.
Dr Vergote on the Efficacy of Tisotumab Vedotin in Recurrent/Metastatic Cervical Cancer
January 8th 2024Ignace B. Vergote, MD, PhD, discusses the efficacy of tisotumab vedotin-tftv in patients with recurrent or metastatic cervical cancer, according to data from the phase 3 innovaTV 301/ENGOT-cx12/GOG-3057 trial (NCT04697628).
Ocular Toxicity Management Strategies for Patients With Cervical Cancer Receiving ADCs
January 3rd 2024Experts detail the management of ocular toxicity associated with tisotumab vedotin in patients with cervical cancer, emphasizing the need for eye care professionals and a team approach, along with addressing peripheral neuropathy.
Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer
January 3rd 2024Dana M. Chase, MD, FACOG, discusses the antibody-drug conjugate tisotumab vedotin including its mechanism of action, its accelerated approval for patients with recurrent cervical cancer and at least one prior line of therapy, and the management of toxicities such as neuropathy and pneumonitis.
Markman Shares Hopes for 2024, Underscoring Need for Meaningful Decision Support Across Oncology
Maurie Markman, MD, discusses current challenges faced with developing robust decision support tools for oncologists and projects additional research efforts dedicated to finding a way to leverage CAR T-cell therapies in solid tumors to improve patient outcomes.
Recent Updates in NCCN Guidelines for the Treatment of Recurrent or Metastatic Cervical Cancer
December 27th 2023Leslie M. Randall, MD, reviews updates to the NCCN guidelines for cervical cancer, including the use of pembrolizumab in the second and third-line settings, the results of the KEYNOTE-826 trial, and the potential role of induction chemotherapy with weekly carboplatin and paclitaxel in the treatment of locally advanced cervical cancer.
Staging and Biomarker Testing For Patients With Cervical Cancer
December 27th 2023David M. O’Malley, MD, discusses cervical cancer epidemiology, risk factors, and diagnosis, highlighting the importance of HPV vaccinations, regular PAP smears, and the use of various biomarkers for treatment decision making.
Clinical Pearls for Community Oncologists Treating Patients With Advanced Endometrial Cancer
December 26th 2023Floor Backes, MD, closes the discussion by explaining that endometrial cancer care is rapidly evolving and complicated, requiring calling on colleagues for guidance, getting molecular profiling, and encouraging trial participation.
Unmet Needs in the Management of Patients With Advanced Endometrial Cancer
December 26th 2023Looking ahead, Floor Backes, MD, notes that key needs in the treatment of advanced endometrial cancer are figuring out next steps when immunotherapy resistance develops, targeted radiation for oligometastatic disease, and sorting patients into subgroups for personalize care.
What Fellows Need to Know: Key Takeaways From ESMO 2023
The 2023 ESMO Congress took place October 20 to 24 in Madrid, Spain, with global perspectives on groundbreaking data. We break down some of the key highlights from the annual meeting that oncology fellows should absorb, and apply to practice, as soon as possible.
FDA Grants Breakthrough Therapy Designation to BNT323/DB-1303 in Endometrial Cancer
December 21st 2023The FDA has granted breakthrough therapy designation to the HER2-targeted antibody-drug conjugate BNT323/DB-1303 for use as a potential therapeutic option in patients with advanced endometrial cancer who have progressed on or after treatment with immune checkpoint inhibitors.
Dostarlimab Plus Chemo Followed by Dostarlimab/Niraparib Improves PFS in Endometrial Cancer
Dostarlimab plus carboplatin and paclitaxel, followed by maintenance dostarlimab and niraparib, significantly improved PFS vs placebo plus chemotherapy followed by placebo in patients with primary advanced or recurrent endometrial cancer, according to data from the phase 3 RUBY trial.
Future Directions in the Treatment of Advanced or Recurrent Endometrial Cancer
December 20th 2023Experts are enthusiastic about the potential of antibody drug conjugates to de-escalate therapy and reduce toxicity in advanced and recurrent endometrial cancer treatment, with a focus on the importance of diversity plans in clinical trials to ensure broader applicability.
Individual Disease Histology and Local Control Are Key Considerations in Endometrial Cancer Care
December 18th 2023Hope Cottrill, MD, highlights practice-changing developments in endometrial cancer care, the benefits of local control with radiation in patients with locally aggressive disease, and questions that remain regarding treatment sequencing with immunotherapy.
Adverse Events Seen With Systemic Therapies in Patients With Advanced Endometrial Cancer
December 18th 2023Drs Backes and Powell discuss the management of adverse events between upfront immunotherapy versus chemotherapy followed by later immunotherapy for endometrial cancer, noting the need for molecular subgroup data from trials like LEAP-001.
Dostarlimab Plus Chemo Granted EU Approval for dMMR/MSI-H Endometrial Cancer
The European Commission has granted marketing authorization to dostarlimab paired with carboplatin and paclitaxel in adults with dMMR/MSI-H primary advanced or recurrent endometrial cancer who are eligible to receive systemic treatment.
Advances in Anti-HER2 ADCs in Patients With Advanced or Recurrent Endometrial Cancer
December 13th 2023Key opinion leaders share excitement about antibody-drug conjugates targeting HER2 in advanced or recurrent endometrial cancer, and debate optimal HER2 testing methods, with some preferring gastric cancer scoring criteria over breast cancer criteria.
Emerging Data on Combination Therapies in Advanced or Recurrent Endometrial Cancer
December 13th 2023The panel reviews results from the ATTEND and DUO-E trials in advanced endometrial cancer, suggesting pembrolizumab remains the standard for the dMMR patient subset while combinations with PARP inhibitors may improve outcomes in pMMR.